GlassScriptPhysician profile
Yasmilka E Sarmiento
NPI 1538443239
$12,315.12
in general payments reported to CMS, 2019-2025
28 companies · $78.01 in 2025
The $78.01 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,049 · 2022: $4,759 · 2023: $4,010 · 2024: $419 · 2025: $78.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,452 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,452.42 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,982.84 | 2021-2025 | |
| Amgen INC. | $1,779.87 | 2021-2023 | Enbrel, Tavneos, Evenity |
| Novartis Pharmaceuticals Corporation | $1,656.57 | 2021-2025 | |
| Ucb, INC. | $796.07 | 2021-2023 | Cimzia |
| Janssen Biotech, INC. | $711.99 | 2021-2023 | Tremfya, Simponi Aria, Simponi |
| Horizon Therapeutics Plc | $619.11 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $550.28 | 2021-2024 | Saphnelo, Airsupra |
| Glaxosmithkline, LLC. | $391.84 | 2021-2023 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $379.35 | 2021-2023 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.18 | 2021-2023 | Ofev |
| Aurinia Pharma U.S., INC. | $276.97 | 2021-2023 | Lupkynis |
| Pfizer INC. | $245.77 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $94.64 | 2021-2022 | |
| Organon LLC | $84.13 | 2021-2023 | Renflexis, Hadlima |
| Alexion Pharmaceuticals, INC. | $56.87 | 2023 | Strensiq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $49.50 | 2022-2023 | Uptravi, Opsumit |
| Lilly USA, LLC | $48.33 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.20 | 2022 | |
| Genzyme Corporation | $26.37 | 2022 | |
| Oxford Immunotec USA INC | $25.82 | 2022 | |
| Radius Health, INC. | $24.38 | 2022 | |
| Paratek Pharmaceuticals, INC. | $24.34 | 2024 | Nuzyra |
| Boston Scientific Corporation | $24.20 | 2021 | |
| Atricure, INC. | $24.07 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.82 | 2024 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $20.10 | 2021 | |
| Genentech USA, INC. | $19.51 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmilka Sarmiento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.